Innovative Trispecific Nanobody Targeting FOLH1 and TNFRSF9 for Next-Generation Cancer Therapy

VHH-P726 is a next-generation humanized nanobody program under biological testing, designed for treatment of cancer by selectively targeting folate hydrolase 1 (FOLH1) and TNF receptor superfamily member 9 (TNFRSF9). This trispecific molecule integrates multiple biologically relevant binding domains to enhance specificity and therapeutic functionality. Engineered for optimized targeting of validated cancer markers, VHH-P726 holds significant potential to address key mechanisms underlying tumor progression and immune modulation. Its rational design supports its candidacy as an advanced therapeutic agent in the evolving landscape of targeted cancer treatments.

Licensing Opportunity

VHH-P726 is available for out-licensing opportunities. We welcome discussions with partners interested in co-development, commercialization, or strategic collaborations to accelerate its path to clinical application.

Development Phase

Modality

VHH-P726 is a trispecific antibody constructed from single-domain antibody fragments, featuring one domain directed against human prostate-specific maturation antigen (PSMA), a second agonistic VH targeting human CD137, and a third directed to human serum albumin, all connected by flexible linkers and (G4S)4 protein regions. The single-domain format confers a compact molecular size, facilitating superior tissue penetration and tumor access relative to conventional antibodies. This architecture enhances molecular stability and decreases immunogenic potential, important attributes in cancer therapy where deep solid tumor targeting is critical. The trispecific design enables simultaneous engagement of tumor and immune targets, paving the way for more potent anti-cancer responses.

Target

FOLH1 and TNFRSF9 are central to the function and value of VHH-P726. FOLH1 is a membrane-bound enzyme with elevated expression in prostate and other tumor tissues, frequently upregulated in malignant cells, making it an established tumor target. TNFRSF9 is an activation-induced costimulatory receptor on immune effector cells, notably T cells and NK cells. TNFRSF9 plays a mechanistic role in potentiating anti-tumor immune responses. The convergence of FOLH1 and TNFRSF9 targeting increases tumor selectivity while activating cellular immunity in the tumor microenvironment. VHH-P726 targets both FOLH1 and TNFRSF9, offering a strategic opportunity to disrupt tumor-promoting biology and enhance immune-mediated eradication of cancer cells, differentiating this asset in the competitive oncology biotherapeutics space.

Mechanism of Action

VHH-P726 combines anti-FOLH1 and anti-TNFRSF9 activities in a single trispecific nanobody format. The anti-FOLH1 domain enables selective binding to tumor cells expressing this antigen, promoting targeted localization. Concurrently, the agonistic anti-TNFRSF9 domain engages and activates costimulatory pathways on immune effector cells, such as T cells, within the tumor microenvironment. This dual targeting may synergize to induce direct tumor cell engagement while simultaneously stimulating robust anti-tumor immunity. The inclusion of domains against serum albumin enhances molecule half-life and systemic circulation. The modular nature of nanobody technology, as exemplified by VHH-P726, supports further platform expansion, enabling development of antibody-drug conjugates or additional bispecific/tri-specific constructs for programmable cancer immunotherapy.

Cancer

Cancer remains a leading cause of morbidity and mortality worldwide, encompassing a heterogeneous group of diseases characterized by uncontrolled cell growth, invasion, and metastasis. The incidence of various cancer types continues to rise globally, placing a significant burden on healthcare systems and society. Current standard treatments include surgery, chemotherapy, radiation, immunotherapies, and targeted agents. While these interventions have improved outcomes, many patients experience disease progression, relapse, or intolerable side effects, signifying considerable unmet medical need. Resistance mechanisms and tumor heterogeneity limit the effectiveness of single-modality approaches. VHH-P726, with its dual-action on FOLH1-expressing cancer cells and immune activation via TNFRSF9, exemplifies a promising therapeutic innovation poised to overcome current treatment bottlenecks. Its unique trispecific architecture aims to deliver greater efficacy, precision, and safety in the management of cancer.